Thrombate III Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of clotting disorders, wider adoption of plasma-derived anticoagulant therapies, expansion of surgical intervention volumes, availability of specialized hematology care, established hospital-based treatment protocols.

The growth in the forecast period can be attributed to increasing surgical procedures in high-risk patients, rising demand for personalized anticoagulation management, expansion of rare blood disorder treatment programs, advancements in plasma fractionation techniques, growing investments in specialty hematology therapeutics. Major trends in the forecast period include increasing use of antithrombin replacement therapies, growing focus on preventive management of coagulation disorders, expansion of perioperative hemostasis protocols, rising awareness of hereditary antithrombin deficiency, improved plasma-derived product purification.

The increasing prevalence of hemophilia is expected to drive the growth of the thrombate III market in the coming years. Hemophilia is a rare genetic disorder in which blood does not clot properly due to a deficiency in essential clotting factors, resulting in prolonged bleeding after injuries, surgeries, or even spontaneous bleeding into joints and muscles. The rising prevalence is linked to genetic mutations, family history, and improved diagnostic methods, which have enhanced detection and reporting. Thrombate III is used in hemophilia treatment to help control bleeding by providing activated antithrombin III, which inhibits clotting factors and prevents excessive bleeding. For example, according to Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, in April 2025 the UK haemophilia A and B patient population exceeded 11,800 individuals during the 2023/24 period, highlighting a sizable and clinically significant treated population. Therefore, the growing prevalence of hemophilia is driving growth in the thrombate III market.

The rise in surgical procedures is also expected to support the growth of the thrombate III market. Surgical procedures involve medical operations performed by healthcare professionals to treat or diagnose conditions, often requiring incisions to access internal areas. The increase in surgical procedures is driven by advancements in medical technology, an aging population, higher prevalence of chronic diseases, improved access to healthcare, and greater awareness of treatment options. Thrombate III aids surgical procedures by providing antithrombin III to prevent excessive blood clotting, particularly in patients with antithrombin III deficiency, reducing risks such as deep vein thrombosis and pulmonary embolism. For instance, according to the National Library of Medicine, a US-based government agency, in August 2024 there was a 3.4% global rise in aesthetic procedures, with a total of 34.9 million surgical and nonsurgical treatments performed by plastic surgeons in 2023, including 15.8 million surgical and 19.1 million nonsurgical procedures worldwide. Consequently, the rise in surgical procedures drives growth in the thrombate III market.

The expansion of healthcare infrastructure is also expected to propel the growth of the thrombate III market. Healthcare infrastructure includes physical facilities, workforce, systems, and resources required to deliver accessible and effective medical services. Growth in infrastructure is driven by the aging population and advancements in medical technology, which create demand for additional facilities and innovative treatments. Enhanced healthcare infrastructure supports thrombate III by providing access to specialized treatments, diagnostic facilities, and skilled healthcare professionals for managing conditions like antithrombin III deficiency. For example, according to the American Health Care Association, a US-based nonprofit organization, in May 2023 the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the expansion of healthcare infrastructure drives growth in the thrombate III market.

Major companies operating in the thrombate iii market are Grifols S.A.

North America was the largest region in the thrombate III market in 2025. The regions covered in the thrombate iii market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombate iii market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are affecting the thrombate III market by increasing costs related to imported plasma inputs, sterile processing materials, biologics-grade packaging, and temperature-controlled logistics systems. North America and Europe are most impacted due to dependence on international plasma sourcing and specialized biologics manufacturing equipment, while other regions face higher treatment acquisition costs. These tariffs may increase hospital procurement expenses and impact therapy accessibility. However, they are also encouraging regional plasma collection initiatives, domestic fractionation capacity expansion, and supply chain diversification.

The thrombate iii market research report is one of a series of new reports that provides thrombate iii market statistics, including thrombate iii industry global market size, regional shares, competitors with a thrombate iii market share, detailed thrombate iii market segments, market trends and opportunities, and any further data you may need to thrive in the thrombate iii industry. This thrombate iii market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thrombate III (antithrombin III [human]) is a prescription medication used to treat or prevent blood clotting disorders in patients with antithrombin III deficiency. It is primarily used in individuals with hereditary antithrombin III deficiency to prevent blood clots, especially during high-risk situations such as surgery or childbirth.

The primary indications for Thrombate III are surgical procedures and hereditary antithrombin deficiency. Surgical procedures are medical operations performed by trained surgeons to manage or treat diseases, injuries, or conditions using instruments, often involving incisions or alterations to the body. Thrombate III is distributed through hospital pharmacies and online pharmacies, serving various patient groups, including adults and elderly patients.

The thrombate III market consists of sales of vials, pre-filled syringes, reconstitution kits, administration kits, and storage and transport kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.